Attached files
| file | filename |
|---|---|
| EX-3.2 - EX-3.2 - Esperion Therapeutics, Inc. | a2215641zex-3_2.htm |
| EX-4.1 - EX-4.1 - Esperion Therapeutics, Inc. | a2215641zex-4_1.htm |
| EX-1.1 - EX-1.1 - Esperion Therapeutics, Inc. | a2215641zex-1_1.htm |
| EX-5.1 - EX-5.1 - Esperion Therapeutics, Inc. | a2215641zex-5_1.htm |
| EX-3.1 - EX-3.1 - Esperion Therapeutics, Inc. | a2215641zex-3_1.htm |
| EX-10.2 - EX-10.2 - Esperion Therapeutics, Inc. | a2215641zex-10_2.htm |
| S-1/A - S-1/A - Esperion Therapeutics, Inc. | a2215641zs-1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and the use of our report dated April 12, 2013 (except Note 1(a) and Note 18, as to which the date is April 19, 2013, and for Note 1(b), as to which the date is June 11, 2013), in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-188595) and related Prospectus of Esperion Therapeutics, Inc. dated June 12, 2013.
/s/ Ernst & Young LLP
Milwaukee, Wisconsin
June 12, 2013